

### Using Patient Preferences to Support Product Development and Value Communication

Most people would recognize that patient preferences have an important role to play in healthcare decision making, although it is only recently that decision makers have shown interest in quantitative methods for eliciting patient preferences.

Demonstrate that endpoints are meaningful to patients

### **GENERATE DECISION RELEVANT INFORMATION**

### **PATIENT PREFERENCE**

- Attribute trade-offs
- Relative importance of attributes and levels

PATIENT PREFERENCE + TREATMENT PERFORMANCE / DECISION ANALYSIS


#### • Minimum acceptable benefit

- Maximum acceptable risk
- Overall benefit risk
- Willingness to pay
- Probability select/adhere to a treatment

### **MEETING REGULATOR AND PAYER REQUIREMENTS**

- The U.S. Food and Drug Administration (FDA) recently made its first regulatory approval based on preference data<sup>1</sup>, and may encourage manufacturers to include patient preference data in submissions under some circumstances.
- The European Medicines Agency (EMA) is assessesing the feasibility and usefulness of methods for eliciting individual patient preferences.
- In Germany, the Institute for Quality and Efficiency in Health Care (IQWiG) has recommended patient preferences are used to inform economic evaluation.

### **INFORM INTERNAL AND EXTERNAL DECISIONS**



<sup>1</sup> http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm430223.htm

### **DISCOVER HOW WE CAN HELP YOU**



DESIGN & IMPLEMENTATION

- Patient-relevant attribute identification
- Patient recruitment
- A diversity of preference elicitation instruments
- Data collection

### **OREVIENTE STRATEGIC INSIGHTS**

- Statistical modeling
- Performance measurement
- Decision analysis

# COMMUNICATE

- Regulatory support
- Payers and HTA bodies
- Scientific dissemination

# Our Team & **EXPERIENCE**

### 15+

Years of experience in preference elicitation and benefit-risk assessment work

### 10+

Staff dedicated to patient-centered benefit-risk assessment; one of the largest teams in the field

### 25+

Peer-reviewed publications related to patient preference

### Global

Experience implementing preference studies in North America, Europe and Asia

## What Makes Us UNIQUE

### Patient Recruitment

Expertise at recruiting patients to ensure representative samples

### Regulatory

Regulatory experts with presence in front of FDA and EMA

### Thought Leaders

Numerous industry leadership roles, e.g., ISPOR MCDA Task Force, ISPOR Stated Preference SIG; ISPE BRACE

